SG Americas Securities
TRDA icon

SG Americas Securities’s Entrada Therapeutics TRDA Stock Holding History

SG Americas Securities’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,036
Closed -$243K – 3763
2024
Q4 		$243K Buy
14,036
+4,291
+44% +$77.7K ﹤0.01% 1968
2024
Q3 		$156K Buy
+9,745
New +$154K ﹤0.01% 2698
2024
Q2 		– Sell
-7,687
Closed -$109K – 3312
2024
Q1 		$109K Sell
7,687
-4,027
-34% -$56.9K ﹤0.01% 2492
2023
Q4 		$177K Buy
11,714
+2,540
+28% +$37.6K ﹤0.01% 2279
2023
Q3 		$145K Buy
+9,174
New +$144K ﹤0.01% 2529

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SG Americas Securities's TRDA Position: Q1 2025 in Review

SG Americas Securities sold out of Entrada Therapeutics (TRDA) in Q1 2025, closing a stake of 14,036 shares — an estimated $243K sold.

SG Americas Securities first reported a position in TRDA in Q3 2023 and held it in 5 quarters. The position peaked at $243K in Q4 2024. 111 funds tracked by Wall St. Rank hold TRDA as of Q1 2025.

  • SG Americas Securities reported no remaining Entrada Therapeutics position as of Q1 2025 after selling out during the quarter.
  • SG Americas Securities sold 14,036 Entrada Therapeutics shares in Q1 2025, an estimated $243K.
  • SG Americas Securities first reported a position in Entrada Therapeutics in Q3 2023 and held it in 5 quarters.
  • SG Americas Securities's Entrada Therapeutics position peaked at $243K in Q4 2024.
  • 111 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2025.

Based on SG Americas Securities's 13F filing for Q1 2025, filed 15 Apr 2025.